Loading
Latest filing published 13 Feb 2026 for Enanta Pharmaceuticals INC. Read the official filing
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Yat Sun Or appears in our data through filings on Enanta Pharmaceuticals Inc shares, published by SEC (Form 4). In total, 22 filings cover trades dated from 4 January 2016 to 12 February 2026.
On the market, this insider has only sold: 3 sales, €70k in total. Outside the open market, there are 12 share grants and 7 option exercises.
The latest filing, published on 13 February 2026, reports a share grant in Enanta Pharmaceuticals Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. For comparison, the SEC allows two business days to file a Form 4. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
22 of 22 declarations